Grogan Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۵۰۰۰۰ • واحد: pg/mL
حداقل ۰ — حداکثر ۵ • واحد: ng/mL
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Stage I—
- Stage II—
- Stage III—
The Grogan Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) calculates stratifying cardiovascular risk, predicting thromboembolic events, or guiding therapeutic interventions. Key inputs include nt probnp. Scores guide initiating guideline-directed medical therapy, antithrombotic or anticoagulant regimens, or urgent coronary angiography. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Classifies prognosis of patients with wild-type transthyretin amyloid cardiomyopathy using cardiac biomarkers NT-proBNP and troponin T
Clinical Indication
The Grogan Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is indicated for bedside clinical practice to support Classifies prognosis of patients with wild-type transthyretin amyloid cardiomyopathy using cardiac biomarkers NT-proBNP and troponin T. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Adult patients presenting with suspected or established coronary artery disease, cardiac arrhythmias, congestive heart failure, or valvular heart defects. Clinical application is indicated across Emergency department, cardiac care unit (CCU), cardiac catheterization laboratory, and outpatient cardiology clinics.
Limitations & Contraindications
In hemodynamically unstable cardiogenic shock, cardiac arrest, or refractory acute coronary syndromes, immediate resuscitation and coronary angiography supersede scoring.
Clinical Pearls & Action Plan
Continuous 12-lead ECG monitoring, serial cardiac troponin measurements, and echocardiographic evaluation align with ESC/ACC/AHA clinical practice guidelines. Guideline pearl: Regular reassessment recommended as biomarkers may change with disease progression or treatment.
Stage I: NT-proBNP ≤3000 pg/mL AND Troponin T ≤0.05 ng/mL; Stage II: One biomarker above threshold; Stage III: Both biomarkers above threshold
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| nt_probnp | float | Yes | N-terminal pro-B-type natriuretic peptide level(pg/mL) |
| troponin_t | float | Yes | Troponin T level(ng/mL) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| — | Stage I | Best prognosis |
| — | Stage II | Intermediate prognosis |
| — | Stage III | Poor prognosis |
Evidence-Based References (EBM)
- Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014-1020. doi: 10.1016/j.jacc.2016.06.033DOI: 10.1016/j.jacc.2016.06.033
- Cappelli F, Baldasseroni S, Bergesio F, et al. Biomarker-based staging system for cardiac transthyretin-related amyloidosis. Eur J Heart Fail. 2020;22(11):2187-2196. doi: 10.1002/ejhf.1898DOI: 10.1002/ejhf.1898
- Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161-172. doi: 10.1016/j.jacc.2016.03.596DOI: 10.1016/j.jacc.2016.03.596